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Abstract 
Background: Standard dosing of meropenem (2 g t.i.d.) produces CSF concentrations of only 1–2 mg/L which is 
inferior to the clinical breakpoint for most Gram-negative bacteria. There is therefore concern that dosing must be 
increased in order to achieve therapeutic CSF concentrations for bacteria with susceptibility close to clinical break-
points. Yet, the effects of high-dose meropenem on CSF concentrations are not well described in literature. We there-
fore determined meropenem CSF-levels in a patient who was treated with 15 g/day of meropenem.
Case presentation: Our patient suffered from a brain trauma and an external ventricular drainage was implanted. 
Later, a carbapenemase-producing Acinetobacter baumannii (OXA-23, NDM-1) was isolated from blood cultures and 
CSF. The MIC for meropenem was > 32 mg/L (R), and we opted for a combination therapy of meropenem, colistin and 
fosfomycin. Meropenem was given at an unusual high-dose (15 g/day) with the aim of achieving high CSF concentra-
tions. CSF concentrations peaked at 64 mg/L. Yet, the patient succumbed to an intracranial bleed into a preexisting 
cerebral contusion.
Conclusions: High-dose meropenem can achieve CSF levels largely superior to those achieved with commonly 
recommended dosing regimens. Though our patient succumbed to an intracranial bleed which could be regarded as 
a severe adverse event, we suggest that meropenem dosing can be increased when pathogens with increased MICs 
are found in the CSF. More in vivo data are however needed to determine the safety of high-dose meropenem.
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Background
Meropenem is a frequently used antimicrobial for post-
neurosurgical meningitis/ventriculitis [1]. It has been 
shown to be clinically effective [1], but its penetration 
into the cerebrospinal fluid (CSF) is not well character-
ized. The median penetration rate ranges from 9 to 39% 
with high inter-individual variation [2, 3]. The efficacy of 
β-lactams such as meropenem depends on the percentage 
of the time that the unbound fraction remains above the 
minimum inhibitory concentration (MIC) of the micro-
organism. According to animal models the target for 
Gram-negative organisms in blood is 40–50% > fT > MIC 
[4] and an important determinant for patient outcome 
[5]. For CSF, the precise pharmacodynamic target is still 
subject of debate. For beta-lactam antibiotics, time above 
the minimal bactericidal concentration (t > MBC) pos-
sibly determines the rate of bactericidal activity in CSF, 
and a t > MBC for more than 50% of the dosing interval 
has been recommended [6]. Yet, no major distinction 
between MIC and MBC was found in several other stud-
ies [6–8], so it is open to debate if MIC or MBC need to 
be targeted. Meningeal inflammation facilitates the pen-
etration of β-lactams into the CNS but most nosocomial 
CSF infections will only result in minimal-to-mild distur-
bances in the blood–CSF barrier [9].
The usual regimen of 2 g meropenem every 8 h results 
in CSF concentrations of 1–2  mg/L which is lower 
than the clinical breakpoint for susceptibility for most 
Gram-negative organisms [10]. Therefore, this regimen 
might be inadequate for the treatment of CNS infec-
tions leading to prolonged courses of treatment as well 
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as patient morbidity and/or mortality. Continuous infu-
sion of β-lactams has also been applied to ensure ade-
quate plasma concentrations [11]. However, data on the 
efficacy of this regimen in meningitis/ventriculitis are 
scarce. Measurement of meropenem CSF concentrations 
has been recommended to ensure clinical efficacy in crit-
ically ill patients [2], although CSF concentrations might 
not exactly mirror brain tissue concentrations. We report 
on a high-dose meropenem regimen in a patient with a 
carbapenem-resistant Acinetobacter baumannii brain 
abscess where relevant CSF concentrations could be 
attained with very high-dose meropenem. To our knowl-
edge, this is the first report on meropenem CSF concen-
tration with such a high-dose regimen.
Case presentation
Our patient developed an intracranial abscess after place-
ment of an external ventricular drain because of a severe 
brain trauma. CSF results are given in Table 1.
A carbapenemase-producing A. baumannii (OXA-23, 
NDM-1) was isolated from blood cultures and CSF. The 
MIC for meropenem was determined using a gradient 
test (MIC-test  strip®, Liofilochem, Roseto degli Abruzzi, 
Italy) and for colistin via commercial broth microdilution 
(Micronaut-S®, Merlin Diagnostika, Bornheim-Hersel, 
Germany). European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) breakpoints were applied. 
The MIC for meropenem was > 32  mg/L (R) and for 
colistin ≤ 1  mg/L (S). Colistin, fosfomycin and merope-
nem were given because clinical data point to improved 
outcomes even in carbapenem-resistant A. baumannii 
infections using combination therapy [12]. Meropenem 
was commenced with 2 g every 6 h, and then increased 
initially to 10 g/day and then to 15 g/day in doses of 2 g 
given over 3  h with a single dose of 1  g/3  h once daily, 
therefore allowing continuous meropenem infusion 
avoiding high peaks and low troughs. Meropenem con-
centrations in plasma and CSF were determined once 
daily during a 2  g dosing interval by HPLC–UV detec-
tion (Fig.  1). The liquid chromatographic system (Agi-
lent 1200) consisted of an HPLC quaternary pump, a 
thermostated oven, a thermostated autosampler, and 
an UV-diode array detector. Separation was achieved at 
45 °C utilizing a Waters X-Bridge analytical column (C18; 
4.6 × 100  mm, 3.5  µm). The mobile phase consisted of 
20 mM potassium dihydrogen phosphate pH 2.6 (mobile 
phase A) and 20  mM potassium dihydrogen phosphate 
pH  2.6 in 50% acetonitrile (mobile phase B). Flow rate 
was 1.5  mL/min and injection volume was 10  µL. The 
autosampler temperature was kept at + 4 °C. UV-absorb-
ance was monitored at 300  nm. The gradient started at 
12% B and increased to 17% B over 5  min and then to 
50% B over 3 min. After a washing step at 95% B for 0.5 
min the column was re-equilibrated at 12% B for 3 min. 
Data analysis was performed using Agilent ChemStation 
software. Proteins were precipitated by adding 400  µL 
Internal Standard solution (40  mg/L cefotaxime in ace-
tonitrile) to 200  µL serum. After vortexing precipitated 
proteins were separated by centrifugation. The super-
natant was mixed with 3 mL of dichloromethane, vigor-
ously vortexed and centrifuged. An aliquot of the upper 
aqueous phase was transferred to an autosampler vial for 
chromatographic analysis.
Since creatinine clearance has been found to be an 
important covariate of meropenem pharmacokinetics 
[13], we monitored renal function closely. The calcu-
lated glomerular filtration rate (CKD-EPI) was ≥ 50 mL/
min/1.73  m2 initially but decreased to 23–40  mL/
min/1.73 m2 after day 26, most probably due to the con-
comitant infusion of colistin. CSF meropenem concen-
trations varied between 31 and 38 mg/L when 10 g/day 
were given over a time period of 12 days. The increased 
dosage of 15 g/day for 3 days resulted in a peak CSF con-
centration of 64 mg/L (Fig. 1). The CSF concentration of 
meropenem was 34–49% of the serum level. Frequent 
vomiting and a gastroparesis were noted as side effects 
whereas there was no effect on hematological or liver 
parameters. No assessment of central nervous side effects 
was possible due to the patient being in coma. Unfortu-
nately, a massive intracranial hemorrhage into the area of 
contusion occurred and the patient died on day 33.
Discussion and conclusions
Commonly recommended meropenem doses for menin-
gitis/ventriculitis are 2 g every 8 h [14]. Yet, meropenem 
penetration into the brain is subject to large inter-indi-
vidual variation and median penetration ratios of as low 
as 9% have been found [2]. Further, it is unclear which 
Table 1 CSF-results during days 1–33
Days 1 5 8 12 15 19 19 23 26 29 33 33 Unit Normal
Leukocyte count (CSF) 108 192 150 88 790 3190 105 274 225 72 1470 540 /μL < 5
Erythrocyte count (CSF) 11 300 3165 1452 9590 7890 5925 387 3100 997 34,500 13,630 /μL 0
Lactate (CSF) 6.5 9.7 8.8 6 7.4 9.5 5.8 5.4 5.7 5.4 7.7 7.3 mmol/dL 1.7–2.6
Total-protein (CSF) 631.8 146.7 145.5 101.6 231.1 168.6 111.6 113.2 197.8 91.1 2956 1824.6 mg/dL 15–40
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percentage of meropenem in the CSF is in the unbound 
active state. Therefore, the CSF concentrations of mero-
penem (6 g/24 h) might not be sufficient to kill bacteria 
with increased MIC (> 2 mg/L) [15]. An augmented renal 
clearance in up to two-thirds of intensive care patients 
possibly also contributes to under-dosing of antibiotics 
[16].
A prolonged 4-h meropenem infusion of 2 g every 8 h 
leads to a probability of a target attainment rate of > 90% 
for most Gram-negative organisms in the blood com-
partment, when the MIC of a Gram-negative organism 
is ≤ 8 mg/L. Monte Carlo simulations suggested that, to 
reach this with the same dosing regimen in CSF, the MIC 
has to be as low as ≤ 0.5  mg/L [17]. In a pharmacoki-
netic model, 5  g meropenem every 8  h were needed to 
achieve CSF trough concentrations of > 2 mg/L in 95.1% 
of simulated patients [2]. Therefore, even the meropenem 
dose of 2 g every 8 h probably fails to achieve a reason-
able target attainment rate in CSF, especially in infections 
with Gram-negative organisms with MICs in the inter-
mediate or resistant range. In our patient, the use of high 
dose-meropenem resulted in CSF concentrations largely 
superior to those reported in the literature when stand-
ard dosing regimens are given. According to our results, 
CSF pathogens with increased meropenem MICs might 
be treated successfully with high-doses of meropenem, 
and our case suggests that an increased meropenem dos-
ing should strongly be considered in such cases. Con-
sidering the highly variable kinetics, therapeutic drug 
monitoring in both serum and CSF seems indispensa-
ble to assure achievement of therapeutic drug concen-
trations. It is, however, unclear if the fatal bleeding was 
related to the high dose of meropenem. Further data are 
therefore necessary to determine the safety of such treat-
ment and if dosing recommendations should be changed.
Abbreviations
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CNS: central 
nervous system; CSF: cerebrospinal fluid; EUCAST: European Committee on 
Antimicrobial Susceptibility Testing; fT: fraction of time; HPLC–UV: high perfor-
mance liquid chromatography–ultraviolet; MIC: minimal inhibitory concentra-
tion; NDM 1: New Delhi metallo-beta-lactamase 1; OXA-23: oxacillinase-23.
Fig. 1 Meropenem doses in g (blue diamonds) during i.v. treatment from day 0 to day 33. Meropenem plasma (red square) and CSF (green triangle) 
levels in mg/L, measured by HPLC-UV detection. X-axis in days, y-axis g/day resp. mg/L
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